Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin

References

• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med. 1987;147:1561–1564.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988.
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute. What is Atrial Fibrillation? [cited 2015 Oct 15]. Available from: http://www.nhlbi.nih.gov/health/health-topics/topics/af.
   Google Scholar
• Ovbiagele B, Goldstein LB, Higashida RT, et al. Forecasting the future of stroke in the United States: a policy statement from the American Heart Association and American Stroke Association. Stroke. 2013;44:2361–2375.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–e322.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol). 2014;64:2246–2280.
   Web of Science ®Google Scholar
• Culebras A, Messé SR, Chaturvedi S, et al. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(8):716–724.
   PubMed Web of Science ®Google Scholar
• Foody JM. Reducing the risk of stroke in elderly patients with non-valvular atrial fibrillation: a practical guide for clinicians. Clin Interv Aging. 2017;12:175–187.
   PubMed Web of Science ®Google Scholar
• Eikelboom J, Merli G. Bleeding with direct oral anticoagulants vs warfarin: clinical experience. Am J Med. 2016;129:S33–S40.
   PubMed Web of Science ®Google Scholar
• Villines TC, Peacock WF. Safety of direct oral anticoagulants: insights from postmarketing studies. Am J Med. 2016;129:S41–S46.
   PubMed Web of Science ®Google Scholar
• Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016;116:975–986.
   PubMed Web of Science ®Google Scholar
• Kansal AR, Zheng Y, Pokora T, et al. Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation. Best Pract Res Clin Haematol. 2013;26:225–237.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ. 2012;15:776–785.
   PubMedGoogle Scholar
• Francis K, Yu C, Alvrtsyan H, et al. Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2015;24:1–7.
   Google Scholar
• Fitch K, Broulette J, Swong WJ. The economic burden of ischemic stroke and major hemorrhage in medicare beneficiaries with nonvalvular atrial fibrillation: a retrospective claims analysis. Am Health Drug Benefits. 2014;7:200–209.
   PubMedGoogle Scholar
• Mercaldi CJ, Siu K, Sander SD, et al. Long-term costs of ischemic stroke and major bleeding events among medicare patients with nonvalvular atrial fibrillation. Cardiol Res Pract. 2012;2012:645469.
   PubMedGoogle Scholar
• D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–2281.
   PubMed Web of Science ®Google Scholar
• Bancroft T, Lim J, Wang C, et al. Health care resource utilization, costs, and persistence in patients newly diagnosed as having nonvalvular atrial fibrillation and newly treated with dabigatran versus warfarin in the United States. Clin Ther. 2016;38:545–556.
   PubMed Web of Science ®Google Scholar
• Mucha L, Masia NA, Azelsen KJ. Per-patient-per-month drug costs in medicare part D protected classes. Pharmacoeconomics. 2006;24:79–84.
   PubMed Web of Science ®Google Scholar
• Anderson RJ. Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service. J Manag Care Pharm. 2004;10:159–165.
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–2870.
   PubMed Web of Science ®Google Scholar
• Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol. 2011;57:173–180.
   PubMed Web of Science ®Google Scholar
• van den Ham HA, Klungel OH, Singer DE, et al. Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke in patients with atrial fibrillation: results from a national primary care database. J Am Coll Cardiol. 2015;66:1851–1859.
   PubMed Web of Science ®Google Scholar
• Roldan V, Marin F, Manzano-Fernandez S, et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013;62:2199–2204.
   PubMed Web of Science ®Google Scholar
• Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20:461–494.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 2016;176:1662–1671.
   PubMed Web of Science ®Google Scholar
• Deitelzweig S, Luo X, Gupta K, et al. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2017;33:1745–1754.
   PubMed Web of Science ®Google Scholar
• Adeboyeje G, Sylwestrzak G, Barron JJ, et al. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2017;23:968–978.
   PubMed Web of Science ®Google Scholar
• Bai Y, Deng H, Shantsila A, et al. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis. Stroke. 2017;48:970–976.
   PubMed Web of Science ®Google Scholar
• Amin A, Keshishian A, Trocio J, et al. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Curr Med Res Opin. 2017;33:1595–1604.
   PubMed Web of Science ®Google Scholar
• Lopes LC, Spencer FA, Neumann I, et al. Bleeding risk in atrial fibrillation patients taking vitamin K antagonists: systematic review and meta-analysis. Clin Pharmacol Ther. 2013;94:367–375.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Oldgren J, Alings M, Darius H, et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011;155:660–667.
   PubMed Web of Science ®Google Scholar
• Bengtson LGS, Lutsey PL, Chen LY, et al. Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation. J Cardiol. 2017;69:868–876.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157–164.
   PubMed Web of Science ®Google Scholar
• Lauffenburger JC, Farley JF, Gehi AK, et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc. 2015;4:pii: e001798.
   PubMed Web of Science ®Google Scholar
• Sussman M, Ghate S, Sutherland SP, et al. Resource use among nonvalvular atrial fibrillation patients. Am J Pharm Benefits. 2016;8:84–92.
   Web of Science ®Google Scholar
• Song X, Gandhi P, Gilligan AM, et al. Comparison of all-cause healthcare resource utilization among patients with non-valvular atrial fibrillation, newly treated with dabigatran or warfarin. Expert Rev Pharmacoecon Outcomes Res. 2017;1–10. [Epub ahead of print]. doi:10.1080/14737167.2017.1347041
   PubMed Web of Science ®Google Scholar
• Gilligan AM, Gandhi P, Song X, et al. Comparison of all-cause healthcare resource utilization and costs among patients with non-valvular atrial fibrillation, newly treated with dabigatran or warfarin. Am J Carsiovasc Drugs. 2017;17:481–492.
   PubMed Web of Science ®Google Scholar
• Gilligan AM, Franchino-Elder J, Song X, et al. Comparison of all-cause healthcare resource use and costs among patients with non-valvular atrial fibrillation newly treated with novel oral anticoagulants. Curr Med Res Opin. 2018;34:285–295.
   PubMed Web of Science ®Google Scholar